Industry News

Daiichi Sankyo Company, Limited has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) for its influenza HA vaccine “Kaketsuken.” As per  Agreement, sales activities of Kaketsuken will begin by Daiichi Sankyo from next season (2015-2016).

[adsense:336x280:8701650588]

Philips has launched the ClearVue Elite range of affordable ultrasound solutions. The product is designed with a high level of performance at an affordable price. This new generation power system has faster processing, superior performance and better output, including faster 4D volume rates that aids in capturing fetal movements. It features Philips proprietary Active Array technology that reduces bulky circuitry and integrates key broadband beam forming capabilities into the transducer, resulting in excellent image quality.

Actavis plc has introduced Namzaric, a once-daily, fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist), and donepezil hydrochloride (an acetylcholinesterase inhibitor) across the United States. Namzaric was approved by the US Food and Drug Administration (FDA) in December for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride.

Eli Lilly and Sanford-Burnham, a non-profit medical research institute, will develop potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders. This high degree of interaction will allow the organizations to flexibly and efficiently advance projects to clinical investigation. The research collaboration will be co-chaired by Thomas F.

AstraZeneca, innovation-driven biopharmaceutical business,  to invest approximately $285 million in a new facility for manufacturing of biological medicines in Södertälje, Sweden. Södertälje is currently main Place to AstraZeneca’s largest global tablets and capsules manufacturing facility. Company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden operations unit.
The new plant will be focused on filling and packaging of protein therapeutics.

Strides Arcolab Limited has got approval from the United States Food & Drug Administration (FDA) for lamivudine and zidovudine tablets USP, 150 mg/300 mg for HIV therapy.

GlaxoSmithKline Pharmaceutical, a leading MNC in India, suffered a setback during the 15 months period ended March 2015 and its consolidated net profit on an annual basis decreased by 20.9 per cent to Rs.381.12 crore from Rs.481.67 crore in the year ended December 2013.

AstraZeneca has entered pact with Abbott  to develop companion diagnostic tests who are most likely to benefit from the investigational biological therapy, tralokinumab. Till now no companion diagnostic blood tests have been approved for use in asthma.

[adsense:336x280:8701650588]

PhoreMost Ltd, a biopharmaceutical company has been selected to receive a funding award of £1.4 mn (approximately $2.14 mn USD) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers. PhoreMost’s lead therapeutic programme has identified drug candidates to a novel synthetic-lethal target for KRAS.

Biotronik, a leading manufacturer of cardio and endovascular medical devices has completed BIOVALVE first-in-human trial for its new transcatheter aortic valve. Biotronik implanted the device in patients suffering from severe symptomatic aortic stenosis.